Trial reportThe Journal of clinical endocrinology and metabolism2014
PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy.
Trial report in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 53 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HEXT: The Hypoparathyroidism Studies, EXTended: The Effect of PTH on the Skeleton in Hypoparathyroidism
CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM
Who cites it
53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Quality of life in patients with hypoparathyroidism receiving standard treatment: an updated systematic review.Endocrine · 2024Pooled it
- Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Pooled it
- Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022Pooled it
- Diagnosis and treatment of hypoparathyroidism: a position statement from the Brazilian Society of Endocrinology and Metabolism.Archives of endocrinology and metabolism · 2018Guideline
- Quality of life in patients with hypoparathyroidism receiving standard treatment: a systematic review.Endocrine · 2017Pooled it
- Impact of recombinant PTH on management of hypoparathyroidism: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2016Pooled it
- Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023Trial
- Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2021Trial
- Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism.The Journal of clinical endocrinology and metabolism · 2018Trial
- Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study.Endocrine · 2017Trial
- Subjective health status, life performance and complications in chronic hypoparathyroidism - a German multicenter survey.Frontiers in endocrinology · 2026Observational
- Phase 1 clinical trial of eneboparatide, a novel PTH receptor 1 agonist.Endocrine connections · 2025Article
- PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide.Current osteoporosis reports · 2025Review
- Improvement of quality of life after 2-month exoskeleton training in patients with chronic spinal cord injury.The journal of spinal cord medicine · 2024Article
- Evaluation of the Quality of Life in Moroccan Patients Diagnosed with Hypoparathyroidism.International journal of endocrinology · 2024Article
- PTH level might be associated with impaired quality of life in patients with nonsurgical hypoparathyroidism.Journal of endocrinological investigation · 2023Article
- Assessment of quality of life in patients with permanent hypoparathyroidism receiving conventional treatment.Journal of diabetes and metabolic disorders · 2023Article
- Challenges in establishing animal models for studying osteoimmunology of hypoparathyroidism.Frontiers in veterinary science · 2023Review
- Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism.Journal of endocrinological investigation · 2022Observational
- Renal complications and quality of life in postsurgical hypoparathyroidism: a case-control study.Journal of endocrinological investigation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
contextIn hypoparathyroidism, quality of life (QOL) is compromised as compared to normal subjects. We previously reported our results showing an association with recombinant human PTH(1-84) therapy in hypoparathyroidism and improvement in QOL measures for 1 year.
objectiveWe tested the hypothesis that PTH(1-84) therapy in hypoparathyroidism through 5 years would be associated with continued improvement in QOL measures.
designSixty-nine hypoparathyroid subjects received open-label PTH(1-84). Before and during therapy, subjects completed the RAND 36-Item Short Form (SF-36) Health Survey, a measure of health-related QOL covering eight domains of physical and mental health.
resultsAt baseline, subjects scored significantly lower than the normative reference range in all 8 domains (T-scores -1.4 to -0.9; P < .001 for all). With PTH therapy, intention-to-treat analysis showed significant improvement in the overall score at 2 months that persisted through 5 years (386 ± 19 to 482 ± 25; P < .0001). The mental component summary score improved at 2 months and was sustained through 5 years (199 ± 11 to 246 ± 14; P = .001), as did all four individual mental health domains and T-scores (vitality, social functioning, role emotional, mental health). The physical component summary score improved at 2 months and was sustained through 5 years (187 ± 10 to 237 ± 13; P < .0001), as did 3 physical health domains and T-scores (physical functioning, role physical, general health).
conclusionsPTH(1-84) therapy is not only associated with improvement in biochemical and skeletal indices, previously well-documented, but also in mental and physical health as determined by the SF-36 metric.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.